<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086939</url>
  </required_header>
  <id_info>
    <org_study_id>ARTROCELL</org_study_id>
    <secondary_id>2019-002446-21</secondary_id>
    <nct_id>NCT05086939</nct_id>
  </id_info>
  <brief_title>Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis (ARTROCELL)</brief_title>
  <acronym>ARTROCELL</acronym>
  <official_title>Phase III, Multicenter, Randomized, Open-label, Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Clinical Research Network - SCReN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, multicenter, randomized, open-label, multicenter clinical trial comparing&#xD;
      treatment with allogeneic mesenchymal cells versus autologous mesenchymal cells and versus&#xD;
      active control with hyaluronic acid in patients with knee osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Open-label, Clinical Trial comparing 3 active treatments.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Range of motion.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of clinical-functional response using Joint range-of-motion evaluation (Flexion score 0º-140º / Extension score -140º-0º /Hiperextension: positive degrees from 0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain self-assessment.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of pain using Visual Analogue Scale (VAS) (Pain self-assessment score range from 0 -no pain- to 10 -maximum-).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee Osteoarthritis.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of Knee Osteoarthritis using Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) [measures five items for pain (score range from 0 -no pain- to 20 -maximum-), two for stiffness (score range from 0-no stiffness- to 8 -maximum-), and 17 for functional limitation (score range from 0 -no limitation- to 68 -maximum-)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional response.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of functional response using Lequesne Algofunctional Index (score range from 0 to 24). It includes measures of pain (5 questions), walking distance (1 question) and activities of daily living (4 questions) with separate versions for the hip and knee. The scores for each question are summed to obtain a combined score of disease severity. Scores 1 to 4 are classified as mild osteoarthrosis; 5 to 7, moderate; 8 to 10, severe; 11 to 13, very severe; and 14 and above, extremely severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>X-ray changes of osteoarthritis.</measure>
    <time_frame>12 months</time_frame>
    <description>Radiological response using Kellgren and Lawrence classification system (grade from 0 to 4):&#xD;
grade 0 (none): definite absence of x-ray changes of osteoarthritis.&#xD;
grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping.&#xD;
grade 2 (minimal): definite osteophytes and possible joint space narrowing.&#xD;
grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space and some sclerosis and possible deformity of bone ends.&#xD;
grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological response using nuclear magnetic resonance imaging.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of radiological response using T2 mapping nuclear magnetic resonance imaging (screening visit global mean of T2 values versus 12 months visit global mean of T2 values).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived general well-being.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Evaluation of quality of life using Short Form-12 Health Survey questionnaire (SF12) [score range from 0 (the worst health status for that dimension) to 100 (the best health status)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of products not conforming to the validation criteria in each arm of experimental treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of presence of adverse events related with investigational medical product (IMP).</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of adverse events and other pharmacovigilance parameters in the three treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Autologous Mesenchymal Stromal Cells (MSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogenic Mesenchymal Stromal Cells (MSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyaluronic Acid 60mg/3ml administered intra-articularly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous MSCs</intervention_name>
    <description>Intra-articular injection 40 million/4 ml.</description>
    <arm_group_label>Autologous Mesenchymal Stromal Cells (MSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogenic MSCs</intervention_name>
    <description>Intra-articular injection 40 million/4 ml.</description>
    <arm_group_label>Allogenic Mesenchymal Stromal Cells (MSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>Intra-articular injection 60mg / 3 ml .</description>
    <arm_group_label>Active Control</arm_group_label>
    <other_name>Hyaluronic Acid 20 mg/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Knee osteoarthritis Kellgren-Lawrence grade 2, 3 or 4 .&#xD;
&#xD;
          2. Chronic painful knee of mechanical characteristics.&#xD;
&#xD;
          3. Absence of local or systemic septic process.&#xD;
&#xD;
          4. Hemacytometric and biochemical analysis without significant alterations that&#xD;
             contraindicate treatment.&#xD;
&#xD;
          5. Written informed consent of the patient.&#xD;
&#xD;
          6. The patient is able to understand the nature of the study.&#xD;
&#xD;
          7. NEGATIVE serologies: Syphilis, HTLVI-II, HIV, Hepatitis B virus (HBV), Hepatitis C&#xD;
             virus (HCV) and HCV PCR (must be repeated if more than 30 days elapse between its&#xD;
             completion and the extraction of bone marrow in patients to whom autologous cells&#xD;
             correspond).&#xD;
&#xD;
          8. Body Mass Index 20-35 Kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient &lt; 18 years old, or legally dependent.&#xD;
&#xD;
          2. Patient &gt; 75 years old.&#xD;
&#xD;
          3. Congenital or evolutive diseases that result in malformation and/or significant&#xD;
             deformities of the knee (varus&lt;10º; valgus&lt;20º) that cause difficulties in the&#xD;
             application and evaluation of the results.&#xD;
&#xD;
          4. Pregnant or breastfeeding women.&#xD;
&#xD;
          5. Neoplastic disease.&#xD;
&#xD;
          6. Intra-articular infiltration of any drug in the 3 months prior to inclusion in the&#xD;
             study.&#xD;
&#xD;
          7. Concurrent participation in another clinical trial or treatment with another&#xD;
             investigational product in the 30 days prior to inclusion in the study.&#xD;
&#xD;
          8. Allergy to gentamicin (antibiotic used in the cell culture process).&#xD;
&#xD;
          9. Other diseases or circumstances that may compromise the participation in the study&#xD;
             according to medical criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fermín Sánchez-Guijo</last_name>
    <role>Principal Investigator</role>
    <affiliation>IBSAL - University Hospital of Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Médico Teknon</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

